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ABSTRACT 
Objective: The main objective of the research work is to develop and characterize allopurinol (ALPN) solid dispersions with different polymers to 
enhance solubility, enrich dissolution profile and improve patient compliance. 
Methods: ALPN solid dispersions were prepared by solvent evaporation technique using various grades of polyethelene glycol (PEG) such as PEG 
4000 and PEG 6000 with different ratios like 1:0.5, 1:1, 1:1.5 and 1:2 and after formation of solid dispersions all physicochemical properties were 
examined.  
Results: All the formulations were found within the permissible pharmacopoeial limits for various physicochemical parameters. The pre-
formulation studies, like Fourier, transform infrared spectroscopy (FTIR) showed the absence of drug-excipient interactions. The solubility and 
dissolution profiles of the sample were increased with increasing the concentration of ALPN solid dispersions. Solvent evaporation was proved to be 
a successful technique for the development of stable solid dispersion of ALPN. The dissolution amount percentage of ALPN formulations was found 
between 39.58±2.5 to 94.95±1.8 % within 60 min. 
Conclusion: Hence, from the all evaluation studies, it was evident that F1 formulation was the better formulation. F1 formulation (ALPN: PEG 4000 
in the ratio of 1:0.5), 94.95±1.8 % drug released within 50 min.  
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From the several previous years, the pharmaceutical scientists were 
working to increase patient compliance and secure dosage forms 
due to the improved requirement in the market for them. As a result, 
developing the novel technologies has been growing annually 
because the growth of novel drug molecules requires higher cost 
rather than novel technology. So the current trend in the greater 
part of pharmaceutical industries is a development of dosage form 
with new formulation technology using old drug molecules to 
improve safety, efficacy and patient compliance [1, 2]. It is active for 
the treatment of both major hyperuricemias of gout and minor 
hyperuricemia related to haematological complaints or anti-
neoplastic therapy [3]. It is a very weak acid with a dissociation 
constant (pKa) of 9.4 and is consequently principally unionized at all 
functional pH values [4]. The aforementioned lipid solubility is 
relatively low as is specified by its octanol: water partition 
coefficient of 0.28 [5]. ALPN is a polar composite thru tough 
intermolecular hydrogen relationship and narrow solubility in 
both polar and non-polar media [6]. Solid dispersion procedures 
used far and wide, to progress the dissolution possessions and 
bioavailability of poorly water-soluble drugs [7]. Solid dispersion 
means for a set of solid products comprising of at least two 
different components, usually a hydrophobic drug and a 
hydrophilic matrix. The matrix can be any crystalline or 
amorphous and drugs can be dispersed molecularly. The 
molecular dispersion can depend on the degree of supersaturation 
and rate of cooling in the process. The important limitation of this 
method is the thermal stability of the drug and the carrier. If 
temperature requires too high, the drug may decompose or 
evaporate. It is furthermore definite as being an origination made 
by fluctuating a fluid drug-carrier amalgamation to the compacted 
state [8]. The intention of the current revision was to prepare 
ALPN solid dispersions by a solvent evaporation method and the 
process for the enhancement of solubility of the drug.  
MATERIALS AND METHODS 
Materials  
ALPN was kindly provided by Sura labs, Hyderabad, Telangana, 
India. PEG 4000, PEG 6000, polyplasdone XL and microcrystalline 
cellulose were purchased from Nihal trader’s Pvt. Ltd., Hyderabad, 
Telangana. Aerosol and magnesium stearate were procured from SD 
Fine-Chemicals limited, Mumbai. Hydrochloric acid (HCl) was 
supplied from Merck Specialities Pvt. Ltd., Mumbai. 
Methods 
Drug-excipient compatibility studies 
Drug-excipient interaction studies carried out by using FTIR, mixing 
the drug and excipients in various proportions. 
Pre-compression studies 
The powder mixtures of all ALPN formulations were evaluated for 
angle of repose, bulk density, tapped density, compressibility index 
and Hausner’s ratio [9].  
Preparation of solid dispersions by solvent evaporation method  
Methanol was used as a solvent. ALPN dose was taken as 100 mg. Water-
soluble polymers such as PEG 4000 and PEG 6000 were selected as 
carriers. Drug and polymers were taken in different ratios such as 1:0.5, 
1:1, 1:1.5, 1:2 stated in the formulation chart (table 1). The prepared 
solid dispersions were passed through the # 20 sieve number to get 
uniform sized particles [10-16]. Add required quantities of diluent, 
lubricant and glidant to the above mixer. The prepared complex samples 
were stored at ambient conditions for further studies [17-18]. 
Preparation of tablets by the direct compression method 
The tablets were prepared by 8 station compression machine using 
10 mm flat surfaced punch. The hardness of the tablets was 
maintained at 4.0-5.0 kg/cm2 [19]. 
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Post-compression studies 
The prepared formulations were categorized with their uniformity 
of weight, thickness, hardness, friability, disintegration time and 
drug content uniformity [20]. 
In vitro drug release studies 
The drug release rate was deliberate using the USP type II 
dissolution test device. The dissolution medium was 900 ml of 
0.1N HCl (pH 1.2) at 50 rpm at a temperature of 37±0.5°C. Samples 
of 5 ml were calm at from time to time up to 60 min. and analyzed 
later proper dilution by using UV visible spectrophotometer at 250 
nm [21]. 
RESULTS AND DISCUSSION 
Drug-excipient compatibility studies 
The drug excipient compatibility study was supported by using 
Fourier transmission infrared spectroscopy (FTIR) and it is shown in 
fig. 1 and fig. 2. They were showing the principal peaks at similar 
wavenumbers. And in the optimized formulation (F1) some different 
wave numbers observed. However, these additional peaks were 
observed with physical mixtures, which could be due to the presence 
of polymers. These results suggest that there is no interaction 
between the drug and polymers used in the present study. Hence the 
excipients are used in this study are inert with drug and are suitable 
for the formulation development. 
 
Table 1: Formulation table showing various compositions 
Ingredients (mg/tab) F1 F2  F3 F4 F5 F6 F7 F8 F9 
Drug 100 100 100 100 100 100 100 100 100 
PEG 4000 50 100 150 200 - - - - 100 
PEG 6000 - - - - 50 100 150 200 100 
Polyplasdone XL  30 30 30 30 30 30 30 30 30 
Aerosil  5 5 5 5 5 5 5 5 5 
Mg. stearate 5 5 5 5 5 5 5 5 5 
MCC q. s q. s q. s q. s q. s q. s q. s q. s q. s 
Total weight of tablets = 500 mg 
 
 
Fig. 1: FTIR spectra of pure drug (ALPN) 
 
 
Fig. 2: FTIR spectra of optimized formulation (F1) 
 









Carr's index* (%) Hausner's ratio* 
F1 28.61±1.202 0.61±0.424 0.61±0.963 10.135±1.12 1.03±0.024 
F2 27.48±0.981 0.48±0.378 0.63±0.896 10.623±0.18 0.99±0.015 
F3 24.01±0.674 0.69±0.912 0.58±0.003 8.977±2.48 1.13±0.028 
F4 24.36±0.267 0.63±1.065 0.61±0.458 9.183±1.06 1.18±0.019 
F5 26.01±0.938 0.66±1.125 0.63±0.955 10.967±0.39 1.17±0.056 
F6 23.80±0.816 0.62±0.089 0.64±0.123 9.825±0.82 1.21±0.029 
F7 24.09±1.045 0.49±0.016 0.69±0.896 8.150±0.91 1.13±0.614 
F8 29.18±0.183 0.66±0.925 0.58±0.912 9.638±1.67 1.22±0.926 
F9 24.47±1.027 0.60±0.141 0.61±0.018 10.901±1.96 1.19±0.034 
Each value represents mean±SD (n=3). 
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Pre-compression studies 
The angle of repose of ALPN was determined by funnel method and 
it was found in the ranges of 24.01±0.674 to 29.18±0.183. Bulk 
density and tapped density was found between 0.66±1.125 to 
0.60±0.141 and 0.61±0.963 to 0.69±0.896 respectively. Carr’s index 
and hausner’s ratios were found to be<11 and<1.25 respectively. 
Pre-compression blends studies representing fair to good flow 
properties and it was shown in table 2. 
Preparation of standard graph 
ALPN standard graph was achieved by various concentrations 
(10 to 59 µg/ml) of drug and correlation coefficient (R2) was 
attained at 0.999. The R2 shows that limit of detection (LOD), 
limit of quantification (LOQ), dynamic range, and limit of 
linearity (LOL).  
Post-compression studies 
The weight variation was found in the ranges from 497±4.24 to 
504±0.23 mg. The hardness (n=6) of the tablets ranged from 
3.9±0.81to 4.8±1.06 kg/cm2 and the friability (n=10) ranged from 
0.298±0.497 %. The thickness (n=20) of the tablets stretched from 
4.92±0.05 to 4.99±0.02 mm and the content of the drug (n=6) is 
98.84±0.76 to 100.35±0.50 %. Consequently, all the physical aspects 
of all formulations were imitated to in the official limits and it was 
shown in table 3. 
 
Table 3: Physical evaluation of ALPN prepared tablets 
Formulation code Weight variationa(mg) Thicknessb (mm) Hardnessc 
(Kg/cm2) 
Friability b (%) Content uniformityc (%) 
F1 500±2.02 4.99±0.84 4.5±0.52 0.492±0.03 102.12±1.43 
F2 498±5.49 4.88±0.06 4.6±0.67 0.499±0.06 98.36±0.78 
F3 497±4.24 4.93±0.01 4.7±0.46 0.496±0.19 99.27±0.47 
F4 502±0.92 4.99±0.06 4.8±0.81 0.501±0.80 102.69±0.36 
F5 498±2.19 4.98±0.07 4.8±0.49 0.499±0.61 96.76±0.91 
F6 503±0.93 4.92±0.05 4.7±0.12 0.492±0.82 98.81±0.46 
F7 504±0.23 4.99±0.02 4.8±0.62 0.502±0.64 99.19±0.66 
F8 498±0.98 4.93±0.02 5.0±0.71 0.498±0.54 100.98±1.09 
F9 502±0.12 4.98±0.06 4.9±0.63 0.499±0.22 98.99±0.09 
a Each value represents mean±S. D (n=20); b Each value represents mean±S. D (n=10); c Each value represents mean±S. D (n=6). 
 
In vitro drug release studies 
The cumulative percentage (%) drug releases (n=3) was shown in 
fig. 3. Based on measurement drug release profiles and other 
physical properties F1 was optimized. As a result F1, initiation 
containing both PEG 4000 and 6000, preferred proportion drug 
release and it follows zero order release kinetics. While the 
preparations comprising PEG 6000 revealed less release and 




Fig. 3: In vitro dissolution data for formulations F1–F9; (n=3) 
 
CONCLUSION 
The dissolution rate can be extensively enhanced by formulating 
ALPN solid dispersion as a compressed tablet and with 
amplification, in the carrier content, there is a rise in the solubility 
also. It could be the best choice of treatment and accomplish good 
patient compliance. To conclude, it was revealed to be a successful 
methodology for illuminating the dissolution rate and thereby 
enhancing its systemic convenience. 
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